[1]
Eichhorn Bilodeau S, Wu BS, Rufyikiri AS, MacPherson S, Lefsrud M. An Update on Plant Photobiology and Implications for Cannabis Production. Frontiers in plant science. 2019:10():296. doi: 10.3389/fpls.2019.00296. Epub 2019 Mar 29
[PubMed PMID: 31001288]
[2]
Auvin S, Damera V, Martin M, Holland R, Simontacchi K, Saich A. The impact of seizure frequency on quality of life in patients with Lennox-Gastaut syndrome or Dravet syndrome. Epilepsy & behavior : E&B. 2021 Oct:123():108239. doi: 10.1016/j.yebeh.2021.108239. Epub 2021 Aug 7
[PubMed PMID: 34375802]
Level 2 (mid-level) evidence
[3]
Strickland JC, Jackson H, Schlienz NJ, Salpekar JA, Martin EL, Munson J, Bonn-Miller MO, Vandrey R. Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. Epilepsy & behavior : E&B. 2021 Sep:122():108205. doi: 10.1016/j.yebeh.2021.108205. Epub 2021 Jul 27
[PubMed PMID: 34311183]
Level 2 (mid-level) evidence
[4]
Schubert-Bast S, Strzelczyk A. Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. Therapeutic advances in neurological disorders. 2021:14():17562864211031100. doi: 10.1177/17562864211031100. Epub 2021 Jul 17
[PubMed PMID: 34349839]
Level 3 (low-level) evidence
[5]
Badowski ME, Yanful PK. Dronabinol oral solution in the management of anorexia and weight loss in AIDS and cancer. Therapeutics and clinical risk management. 2018:14():643-651. doi: 10.2147/TCRM.S126849. Epub 2018 Apr 6
[PubMed PMID: 29670357]
[6]
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Aug 20:38(24):2782-2797. doi: 10.1200/JCO.20.01296. Epub 2020 Jul 13
[PubMed PMID: 32658626]
[7]
Rice J, Hildebrand A, Spain R, Senders A, Silbermann E, Wooliscroft L, Yadav V, Bourdette D, Cameron M. A cross-sectional survey of cannabis use by people with MS in Oregon and Southwest Washington. Multiple sclerosis and related disorders. 2021 Oct:55():103172. doi: 10.1016/j.msard.2021.103172. Epub 2021 Jul 25
[PubMed PMID: 34332457]
Level 2 (mid-level) evidence
[8]
Pantoja-Ruiz C, Restrepo-Jimenez P, Castañeda-Cardona C, Ferreirós A, Rosselli D. Cannabis and pain: a scoping review. Brazilian journal of anesthesiology (Elsevier). 2022 Jan-Feb:72(1):142-151. doi: 10.1016/j.bjane.2021.06.018. Epub 2021 Jul 16
[PubMed PMID: 34280454]
Level 2 (mid-level) evidence
[9]
Spanagel R, Bilbao A. Approved cannabinoids for medical purposes - Comparative systematic review and meta-analysis for sleep and appetite. Neuropharmacology. 2021 Sep 15:196():108680. doi: 10.1016/j.neuropharm.2021.108680. Epub 2021 Jun 26
[PubMed PMID: 34181977]
Level 2 (mid-level) evidence
[10]
Premoli M, Aria F, Bonini SA, Maccarinelli G, Gianoncelli A, Pina SD, Tambaro S, Memo M, Mastinu A. Cannabidiol: Recent advances and new insights for neuropsychiatric disorders treatment. Life sciences. 2019 May 1:224():120-127. doi: 10.1016/j.lfs.2019.03.053. Epub 2019 Mar 22
[PubMed PMID: 30910646]
Level 3 (low-level) evidence
[11]
Borgelt LM, Franson KL, Nussbaum AM, Wang GS. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013 Feb:33(2):195-209. doi: 10.1002/phar.1187. Epub
[PubMed PMID: 23386598]
[12]
Benito C, Núñez E, Tolón RM, Carrier EJ, Rábano A, Hillard CJ, Romero J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2003 Dec 3:23(35):11136-41
[PubMed PMID: 14657172]
[13]
Chiarotti M, Costamagna L. Analysis of 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in biological samples by gas chromatography tandem mass spectrometry (GC/MS-MS). Forensic science international. 2000 Oct 9:114(1):1-6
[PubMed PMID: 10924845]
[14]
Musshoff F, Madea B. Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Therapeutic drug monitoring. 2006 Apr:28(2):155-63
[PubMed PMID: 16628124]
[16]
Sharma P, Murthy P, Bharath MM. Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iranian journal of psychiatry. 2012 Fall:7(4):149-56
[PubMed PMID: 23408483]
[17]
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical pharmacokinetics. 2003:42(4):327-60
[PubMed PMID: 12648025]
[18]
Steigerwald S, Wong PO, Khorasani A, Keyhani S. The Form and Content of Cannabis Products in the United States. Journal of general internal medicine. 2018 Sep:33(9):1426-1428. doi: 10.1007/s11606-018-4480-0. Epub
[PubMed PMID: 29770952]
[21]
Volkow ND, Han B, Einstein EB, Compton WM. Prevalence of Substance Use Disorders by Time Since First Substance Use Among Young People in the US. JAMA pediatrics. 2021 Jun 1:175(6):640-643. doi: 10.1001/jamapediatrics.2020.6981. Epub
[PubMed PMID: 33779715]
[22]
Han BH, Brennan JJ, Orozco MA, Moore AA, Castillo EM. Trends in emergency department visits associated with cannabis use among older adults in California, 2005-2019. Journal of the American Geriatrics Society. 2023 Apr:71(4):1267-1274. doi: 10.1111/jgs.18180. Epub 2023 Jan 9
[PubMed PMID: 36622838]
[23]
Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC. The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction (Abingdon, England). 2013 Jan:108(1):124-33. doi: 10.1111/j.1360-0443.2012.04015.x. Epub 2012 Oct 18
[PubMed PMID: 22775447]
[24]
Posis A, Bellettiere J, Liles S, Alcaraz J, Nguyen B, Berardi V, Klepeis NE, Hughes SC, Wu T, Hovell MF. Indoor cannabis smoke and children's health. Preventive medicine reports. 2019 Jun:14():100853. doi: 10.1016/j.pmedr.2019.100853. Epub 2019 Mar 16
[PubMed PMID: 30976488]
[25]
Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ (Clinical research ed.). 2019 Apr 4:365():l1141. doi: 10.1136/bmj.l1141. Epub 2019 Apr 4
[PubMed PMID: 30948383]
[26]
Ugradar S, Manta A, Flanagan D. Unilateral cilioretinal artery occlusion following cannabis use. Therapeutic advances in ophthalmology. 2019 Jan-Dec:11():2515841419838661. doi: 10.1177/2515841419838661. Epub 2019 Mar 27
[PubMed PMID: 30944891]
Level 3 (low-level) evidence
[27]
Drummer OH, Gerostamoulos D, Woodford NW. Cannabis as a cause of death: A review. Forensic science international. 2019 May:298():298-306. doi: 10.1016/j.forsciint.2019.03.007. Epub 2019 Mar 14
[PubMed PMID: 30925348]
[28]
Mustonen A, Niemelä S, Nordström T, Murray GK, Mäki P, Jääskeläinen E, Miettunen J. Adolescent cannabis use, baseline prodromal symptoms and the risk of psychosis. The British journal of psychiatry : the journal of mental science. 2018 Apr:212(4):227-233. doi: 10.1192/bjp.2017.52. Epub
[PubMed PMID: 29557758]
[29]
Stefani A, Aramini B, Baraldi C, Pellesi L, Della Casa G, Morandi U, Guerzoni S. Secondary spontaneous pneumothorax and bullous lung disease in cannabis and tobacco smokers: A case-control study. PloS one. 2020:15(3):e0230419. doi: 10.1371/journal.pone.0230419. Epub 2020 Mar 30
[PubMed PMID: 32226050]
Level 2 (mid-level) evidence
[30]
Meier MH, Caspi A, Cerdá M, Hancox RJ, Harrington H, Houts R, Poulton R, Ramrakha S, Thomson WM, Moffitt TE. Associations Between Cannabis Use and Physical Health Problems in Early Midlife: A Longitudinal Comparison of Persistent Cannabis vs Tobacco Users. JAMA psychiatry. 2016 Jul 1:73(7):731-40. doi: 10.1001/jamapsychiatry.2016.0637. Epub
[PubMed PMID: 27249330]
[31]
Callaghan RC, Sanches M, Kish SJ. Quantity and frequency of cannabis use in relation to cannabis-use disorder and cannabis-related problems. Drug and alcohol dependence. 2020 Dec 1:217():108271. doi: 10.1016/j.drugalcdep.2020.108271. Epub 2020 Sep 11
[PubMed PMID: 32977043]
[32]
Auer R, Vittinghoff E, Yaffe K, Künzi A, Kertesz SG, Levine DA, Albanese E, Whitmer RA, Jacobs DR Jr, Sidney S, Glymour MM, Pletcher MJ. Association Between Lifetime Marijuana Use and Cognitive Function in Middle Age: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. JAMA internal medicine. 2016 Mar:176(3):352-61. doi: 10.1001/jamainternmed.2015.7841. Epub
[PubMed PMID: 26831916]
[33]
Lapoint J, Meyer S, Yu CK, Koenig KL, Lev R, Thihalolipavan S, Staats K, Kahn CA. Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline. The western journal of emergency medicine. 2018 Mar:19(2):380-386. doi: 10.5811/westjem.2017.11.36368. Epub 2017 Nov 8
[PubMed PMID: 29560069]
[34]
Chadi N, Levy S. What Every Pediatric Gynecologist Should Know About Marijuana Use in Adolescents. Journal of pediatric and adolescent gynecology. 2019 Aug:32(4):349-353. doi: 10.1016/j.jpag.2019.03.004. Epub 2019 Mar 26
[PubMed PMID: 30923025]
[35]
Giano Z, Hubach RD, Currin JM, Wheeler DL. Adverse childhood experiences and MSM marijuana use. Drug and alcohol dependence. 2019 May 1:198():76-79. doi: 10.1016/j.drugalcdep.2019.01.024. Epub 2019 Feb 27
[PubMed PMID: 30878770]
[36]
Gundersen TD, Jørgensen N, Andersson AM, Bang AK, Nordkap L, Skakkebæk NE, Priskorn L, Juul A, Jensen TK. Association Between Use of Marijuana and Male Reproductive Hormones and Semen Quality: A Study Among 1,215 Healthy Young Men. American journal of epidemiology. 2015 Sep 15:182(6):473-81. doi: 10.1093/aje/kwv135. Epub 2015 Aug 16
[PubMed PMID: 26283092]
Level 2 (mid-level) evidence
[37]
Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life sciences. 2007 Mar 20:80(15):1415-9
[PubMed PMID: 17303175]
[38]
Antoniou T, Bodkin J, Ho JM. Drug interactions with cannabinoids. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2020 Mar 2:192(9):E206. doi: 10.1503/cmaj.191097. Epub
[PubMed PMID: 32122975]
[39]
Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar D. The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accident; analysis and prevention. 2010 Nov:42(6):1855-65. doi: 10.1016/j.aap.2010.05.006. Epub 2010 Jun 9
[PubMed PMID: 20728636]
[40]
Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018 Apr 3:90(14):e1204-e1211. doi: 10.1212/WNL.0000000000005254. Epub 2018 Mar 14
[PubMed PMID: 29540584]
Level 1 (high-level) evidence
[41]
Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS drugs. 2020 Jun:34(6):661-672. doi: 10.1007/s40263-020-00726-4. Epub
[PubMed PMID: 32350749]
Level 1 (high-level) evidence
[42]
Wray L, Berwaerts J, Critchley D, Hyland K, Chen C, Thai C, Tayo B. Pharmacokinetic Drug-Drug Interaction With Coadministration of Cannabidiol and Everolimus in a Phase 1 Healthy Volunteer Trial. Clinical pharmacology in drug development. 2023 Sep:12(9):911-919. doi: 10.1002/cpdd.1262. Epub 2023 May 3
[PubMed PMID: 37132402]
[43]
Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology. 2018 Nov:84(11):2477-2482. doi: 10.1111/bcp.13710. Epub 2018 Aug 7
[PubMed PMID: 30001569]
[44]
Reisfield GM. Medical cannabis and chronic opioid therapy. Journal of pain & palliative care pharmacotherapy. 2010 Dec:24(4):356-61. doi: 10.3109/15360288.2010.519431. Epub
[PubMed PMID: 21133743]
[45]
Skypala IJ, Jeimy S, Brucker H, Nayak AP, Decuyper II, Bernstein JA, Connors L, Kanani A, Klimek L, Lo SCR, Murphy KR, Nanda A, Poole JA, Walusiak-Skorupa J, Sussman G, Zeiger JS, Goodman RE, Ellis AK, Silvers WS, Ebo DG, International Cannabis Allergy Collaboration. Cannabis-related allergies: An international overview and consensus recommendations. Allergy. 2022 Jul:77(7):2038-2052. doi: 10.1111/all.15237. Epub 2022 Feb 14
[PubMed PMID: 35102560]
Level 3 (low-level) evidence
[46]
Hoffman BC, Kuhl M, Harbeck RJ, Rabinovitch N. Cannabis allergy in a child with asthma chronically exposed to marijuana. The journal of allergy and clinical immunology. In practice. 2020 Jan:8(1):422-423. doi: 10.1016/j.jaip.2019.06.042. Epub 2019 Jul 16
[PubMed PMID: 31323337]
[47]
Szyper-Kravitz M, Lang R, Manor Y, Lahav M. Early invasive pulmonary aspergillosis in a leukemia patient linked to aspergillus contaminated marijuana smoking. Leukemia & lymphoma. 2001 Nov-Dec:42(6):1433-7
[PubMed PMID: 11911432]
[48]
Thompson GR 3rd, Tuscano JM, Dennis M, Singapuri A, Libertini S, Gaudino R, Torres A, Delisle JM, Gillece JD, Schupp JM, Engelthaler DM. A microbiome assessment of medical marijuana. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017 Apr:23(4):269-270. doi: 10.1016/j.cmi.2016.12.001. Epub 2016 Dec 9
[PubMed PMID: 27956269]
[49]
Cavazos-Rehg PA, Krauss MJ, Cahn E, Lee KE, Ferguson E, Rajbhandari B, Sowles SJ, Floyd GM, Berg C, Bierut LJ. Marijuana Promotion Online: an Investigation of Dispensary Practices. Prevention science : the official journal of the Society for Prevention Research. 2019 Feb:20(2):280-290. doi: 10.1007/s11121-018-0889-2. Epub
[PubMed PMID: 29629505]
[50]
Kahan M, Srivastava A. New medical marijuana regulations: the coming storm. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2014 Sep 2:186(12):895-6. doi: 10.1503/cmaj.131821. Epub 2014 Jun 23
[PubMed PMID: 24958833]
[51]
Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug and alcohol dependence. 2001 Nov 1:64(3):319-27
[PubMed PMID: 11672946]
[53]
Wolfe CE, Wood DM, Dines A, Whatley BP, Yates C, Heyerdahl F, Hovda KE, Giraudon I, Dargan PI, Euro-DEN Research Group. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set. Neurotoxicology. 2019 Jul:73():183-187. doi: 10.1016/j.neuro.2019.04.003. Epub 2019 Apr 8
[PubMed PMID: 30974132]
[54]
Koltai H, Poulin P, Namdar D. Promoting cannabis products to pharmaceutical drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2019 Apr 30:132():118-120. doi: 10.1016/j.ejps.2019.02.027. Epub 2019 Mar 7
[PubMed PMID: 30851400]
[55]
Ashton CH. Pharmacology and effects of cannabis: a brief review. The British journal of psychiatry : the journal of mental science. 2001 Feb:178():101-6
[PubMed PMID: 11157422]
[56]
Appelboam A, Oades PJ. Coma due to cannabis toxicity in an infant. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2006 Jun:13(3):177-9
[PubMed PMID: 16679885]
[57]
Kulig K. Interpretation of Workplace Tests for Cannabinoids. Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2017 Mar:13(1):106-110. doi: 10.1007/s13181-016-0587-z. Epub 2016 Sep 29
[PubMed PMID: 27686239]
[58]
Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. The American journal of emergency medicine. 2013 Jun:31(6):1003.e5-6. doi: 10.1016/j.ajem.2013.02.021. Epub 2013 Apr 10
[PubMed PMID: 23583118]
[59]
Wisk LE, Levy S, Weitzman ER. Parental views on state cannabis laws and marijuana use for their medically vulnerable children. Drug and alcohol dependence. 2019 Jun 1:199():59-67. doi: 10.1016/j.drugalcdep.2018.12.027. Epub 2019 Feb 14
[PubMed PMID: 30999251]
[60]
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS drugs. 2019 May:33(5):417-430. doi: 10.1007/s40263-019-00627-1. Epub
[PubMed PMID: 30977108]
[61]
Friedman D, French JA, Maccarrone M. Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders. The Lancet. Neurology. 2019 May:18(5):504-512. doi: 10.1016/S1474-4422(19)30032-8. Epub 2019 Mar 22
[PubMed PMID: 30910443]
[62]
Rickles NM, Wakai S, Karim-Nejad L. The use of an integrated opioid and medical marijuana prescription drug monitoring program. Journal of the American Pharmacists Association : JAPhA. 2021 Jul-Aug:61(4):408-417. doi: 10.1016/j.japh.2021.02.020. Epub 2021 Mar 4
[PubMed PMID: 33903060]